SAN DIEGO — Biogen on Thursday presented detailed data making a case for its resurrected Alzheimer’s drug, arguing that its mixed study results can be explained away by differences in whether patients got the highest dose of the medicine.

But the new data deepen sharp questions about the prospects of the drug and are unlikely to convince skeptics who doubt whether the Food and Drug Administration will be willing to approve it. Biogen’s stock was up 1.75% midday on Thursday after its presentation here at the Alzheimer’s research conference known as CTAD.

Unlock this article by subscribing to STAT Plus. To get you started, enjoy 50% off your first 3 months!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

  • I was on the Ninewells,Dundee drug trial,aducanumab or placebo. People like me with cognitive impairment have lost a prospective lifeline & hopes have been dashed by the cessation of the trial. It’s difficult for a lay person to interpret these results. I was then invited to restart this trial only to read the future is unclear. Myself & others are struggling to stay positive meantime…..

Your daily dose of news in health and medicine

Privacy Policy